TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06699212: A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Dist

Sponsor: Rakuten Medical, Inc. · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 412 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$8,790,936

Rescue Site Savings

+$5,773,152

Unlock Full NCT06699212 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06699212 Rescue Dossier →